# Allysta Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/allysta-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Belmont, US
- Website: www.allysta.com
- Total disclosed funding: $15M
- Latest round: Series A (Apr 16, 2019)
- Investors on record: 1

## About

Allysta Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative treatments for rare diseases, particularly through its advanced formulation, ALY688ER, which targets significant unmet medical needs.Founded in 2013, Allysta Pharmaceuticals, Inc. is based in Belmont, US. The company specializes in biopharmaceutical products aimed at rare diseases. In April 2019, they raised USD 15 mn in Series A funding from Morningside Venture Capital, marking a pivotal moment in their fundraising efforts. The CEO, Henry Hsu, leads the company’s mission to develop therapies for conditions like Duchenne muscular dystrophy (DMD).Allysta Pharmaceuticals specializes in developing innovative biopharmaceutical products targeting rare diseases with significant unmet medical needs. The company's core product offering is ALY688ER, an extended-release formulation designed to deliver the active compound ALY688 throughout the body efficiently. ALY688 functions as a potent and selective activator of adiponectin signaling pathways, which are critical for regulating metabolic processes and combating conditions associated with obesity. The primary end use case for ALY688ER is in the treatment of Duchenne muscular dystrophy (DMD), a severe genetic disorder affecting boys, characterized by progressive muscle degeneration. The product has shown promising results in preclinical models, including reduced muscle cell death and enhanced muscle regeneration. While the company is focused on bringing its products to the U.S. market, it also aims to expand its reach into international markets, where there is a high prevalence of rare diseases and a pressing demand for effective therapies.Allysta Pharmaceuticals operates within a transactional framework primarily based on partnerships and direct sales to healthcare providers. The company's revenue model is expected to involve agreements with healthcare institutions and possibly collaborations with larger pharmaceutical companies for broader distribution. Transactions involve the sale of ALY688ER as part of a therapeutic regimen for patients diagnosed with DMD and potentially other inflammatory and fibrotic conditions. The pricing structure for its products is designed to reflect the advanced therapeutic benefits provided by ALY688ER, which addresses critical health challenges faced by patients. The firm focuses on building relationships with clinicians and institutions to ensure access to its innovative treatments, thereby creating a sustainable revenue stream through the provision of high-value medical solutions.Allysta Pharmaceuticals plans to utilize the recent Series A funding of USD 15 mn raised in April 2019 to further develop and bring new products to market, including enhancements to ALY688ER. The company is targeting expansion into international markets known for high incidences of rare diseases, with specific plans to enter these regions by 2024. Furthermore, the company intends to increase its partnerships with healthcare institutions to facilitate broader distribution and enhance accessibility of its therapies.

## Funding rounds

- Series A, Apr 16, 2019, $15M — 5Y Capital

## Investors

- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series A